An  article appeared in the AFR this week. ‘Billion-dollar molecule’ may extend life in men with prostate cancer – Australian Financial Review, May 9 2018 It concerns a clinical trial being conducted in Australia of a promising experimental form of therapy for late-stage prostate cancer. I have been asked where our efforts with NOX66 in […]

Since Noxopharm’s ASX release last Wednesday about seeing abscopal responses in two patients receiving NOX66, some shareholders have asked me what it means to the future treatment of cancer. The short answer is, potentially a great deal. By any definition, it is ‘disruptive technology’ that has the potential to change the face of cancer therapy. […]

It’s been 9 months in the making, and a good deal of hard work, but finally our US subsidiary, Nyrada, Inc. is launched with the successful closing of a $4M capital raise. What does Nyrada mean to me as a NOX shareholder? As a NOX shareholder, through NOX, you now have a ‘stake’ in a […]

In response to shareholder enquiry, this is a clarifying note about the agreement recently entered into between NOX and KZA. The agreement represents a commercial decision reached by both parties that provides NOX with the certainty it needs as it prepares to enter a Phase 2/Phase 3 clinical program for its lead drug candidate, NOX66. […]

  The two key tests in being awarded a patent over any intellectual property (IP) are novelty and inventiveness. In the drug development world, proving both is much easier where there is no pre-existing IP…. For example, no-one had described the new molecule before (known as a New Chemical Entity), so it is novel; or […]

A short note on the clinical data we presented at ESMO. This is early data from our first-in-human clinical study, so it is important to keep that perspective. Over the course of the next 6 months we plan on reporting on this and other clinical studies at various international and local oncology conferences. Progressively, the […]

Is it possible that Noxopharm can do something meaningful for patients with brain cancer, where so many others have failed? We believe so, with our recent announcement going some way to justifying that belief. Yes, what we have just announced is laboratory data. And, yes, we have a long way to go before we can […]

Unless you have had prostate cancer, or graduated in medicine, or hold a PhD in physics, chances are you have never heard of the terms radiotherapy brachytherapy and 177-lutetium-PSMA peptide complex. So here goes with an explanation…an easy one first and then a more in-depth explanation if you are up to it. Simple explanation: a […]

The following are some questions generated by last Thursday’s announcement. Q: Why are we planning on running 7 clinical studies? A: Because we want to be in a Phase 3 registration study in 2019, and that means knowing by the end of 2018 what that study will look like. We also want that Phase 3 […]

Our last announcement (27th March) reported on two developments. Both relating to some research being done under contract for Noxopharm by Monash University and partially funded by the Federal Government. First development:   idronoxil-C  Q. What is idronoxil-C? A.  Idronoxil-C is an exciting development that we believe has increased very considerably the value of the Company’s […]

Our primary focus remains to bring NOX66 to market to make both chemotherapy and radiotherapy work better and at lower, safer dosages. However, we now can reveal a tantalizing opportunity that is being incorporated into our trials for minimal additional cost. Last Friday’s announcement introduced that opportunity, as well as a new word for most […]

We have yet to treat our first patient with NOX66, but the clinical program has started. Splitting hairs? Perhaps, but starting any first-in-man study is an exercise in logistics. Getting a program of 5 clinical studies up and running is a considerable task. We have cleared the major hurdles on all 5 studies: viz. manufacture […]

The results of a recent study endorse the approach being taken by Noxopharm in using NOX66 to allow low dosages of chemotherapy to be used…much lower than currently in general use. The obvious advantage we are pursuing with NOX66 is that chemotherapy potentially could be used at levels unlikely to cause any side-effects, making life […]

Our AGM last Wednesday in Melbourne and General Briefing last Friday in Sydney brought out some questions from the floor that I thought it worthwhile mentioning for those not able to attend.   Q.Are we looking to raise capital? No. We have sufficient funds to take us through to 2018. If we are successful in […]

The details about the Phase 1 study announced yesterday are available at: https://clinicaltrials.gov/show/NCT02941523 Our main objective in this study is to see if NOX66 can make tumours respond to chemotherapy once they have become fully drug-resistant, and to do so using low dosages of chemotherapy. That’s an ambitious and novel objective, but one that in […]

It’s been 2 months since the listing and IPO. The first few months in the life of a drug development company is all about laying foundations. Everyone is looking for news flow as evidence of activity, but that requires first building the platforms that will deliver the news flow.  As the platforms are progressively built, […]

In a recent ASX announcement, we made mention of opening up a second clinical front for NOX66, that being to use it in conjunction with radiotherapy.   Our objective is to open up two Phase 1 studies of NOX66 + radiotherapy over the next 6 months. These will complement the NOX66 + chemotherapy study we […]

SEPTEMBER 5, 2016:   NOX66 TECHNOLOGY EXPLAINED       by Dr Graham Kelly   Here is an obvious question: Idronoxil was tested in over 400 cancer patients over a 10-year period. In the end, it didn’t work in enough patients to warrant the investment to continue to bring it to market. So why do we think we can […]

Welcome to this first blog, which I will use to expand on the details of our upcoming clinical study. It’s a somewhat unusual design, so worth a moment or two to look at in some detail. The first thing to comment on is why we are conducting the study in Eastern Europe and not Australia. […]